Page last updated: 2024-10-28

hypericin and Neoplasms

hypericin has been researched along with Neoplasms in 41 studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"To study whether formulation influences biodistribution, necrosis avidity and tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting anticancer radiotherapy."7.80Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014)
"In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors."5.42Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015)
"To study whether formulation influences biodistribution, necrosis avidity and tumoricidal effects of the radioiodinated hypericin, a necrosis avid agent for a dual-targeting anticancer radiotherapy."3.80Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. ( Alpizar, YA; Bauwens, M; Chen, F; Cona, MM; de Witte, P; Feng, Y; Li, J; Ni, Y; Oyen, R; Sun, Z; Talavera, K; Verbruggen, A; Zhang, J, 2014)
"Hypericin is a prominent secondary metabolite mainly existing in genus Hypericum."3.01Hypericin: A natural anthraquinone as promising therapeutic agent. ( Ding, K; He, J; Li, XX; Pan, XG; Wu, JJ; Xia, CY; Xu, JK; Zhang, J; Zhang, WK, 2023)
"Hypericin is a polycyclic aromatic naphthodianthrone that occurs naturally."2.72Hypericin-mediated photodynamic therapy for the treatment of cancer: a review. ( Cruz, LJ; Dong, X; Fu, J; Gu, Z; Hao, Y; He, Y; Ni, J; Qu, C; Yin, X; You, L; Yu, Z; Zeng, Y; Zhang, Z, 2021)
"Hypericin (HY) is an interesting photosensitizer with dark activity and photodynamic therapy (PDT) effects via p53-independent pathway."2.44Potentiation of the photodynamic action of hypericin. ( Heng, PW; Olivo, M; Saw, CL, 2008)
"Hypericin is a naturally occurring substance found in the common St."2.43Hypericin--the facts about a controversial agent. ( Alth, G; Burner, U; Grünberger, W; Kubin, A; Wierrani, F, 2005)
"Hypericin is a naturally occurring secondary metabolite in plants of the Hypericum genus, with Hypericum perforatum (St."2.43Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. ( Kiesslich, T; Krammer, B; Plaetzer, K, 2006)
"Hypericin aggregates were confirmed by absorption spectra typical of aggregated hypericin and by its short fluorescence lifetime."1.91Effective transport of aggregated hypericin encapsulated in SBA-15 nanoporous silica particles for photodynamic therapy of cancer cells. ( Almáši, M; Benziane, A; Girman, V; Huntošová, V; Miklóšová, M; Pevná, V; Vámosi, G; Zauška, Ľ; Zeleňák, V, 2023)
" A marked decrease in the glutathione level of a majority of cells was observed after more toxic combination treatment."1.42Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status. ( Fedoročko, P; Jendželovská, Z; Jendželovský, R; Kovaľ, J; Kuchárová, B; Mikeš, J; Mikešová, L; Vargová, J, 2015)
"In conclusion, NTRT improved the anticancer efficacy of VDT in rabbits with VX2 tumors."1.42Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. ( Chen, F; Dai, X; Li, Y; Ni, Y; Shao, H; Sun, Z; Xu, K; Zhang, J, 2015)
"Moreover, we found that a subset of cancer patients of various cancer-types indeed possessed CALRlow or CRTlow-tumours."1.42Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. ( Agostinis, P; de Witte, P; Elsen, S; Garg, AD; Krysko, DV; Vandenabeele, P, 2015)
"Autophagy-attenuated cancer cells displayed enhanced ecto-CALR induction following Hyp-PDT, which strongly correlated with their inability to clear oxidatively damaged proteins."1.39ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. ( Agostinis, P; Dudek, AM; Ferreira, GB; Garg, AD; Krysko, DV; Mathieu, C; Vandenabeele, P; Verfaillie, T, 2013)
"Hypericin was conjugated to biotin-ethylenediamine in a straightforward coupling method using n-hydroxysuccinimide and dicyclohexylcarbodiimide."1.38Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy. ( Bauwens, M; Bormans, G; de Witte, P; Marysael, T; Ni, Y; Rozenski, J, 2012)
"Here, we show that when cancer cells are treated with hypericin-based PDT (Hyp-PDT), they surface-expose both HSP70 and calreticulin (CRT)."1.38Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. ( Agostinis, P; Garg, AD; Krysko, DV; Vandenabeele, P, 2012)

Research

Studies (41)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (21.95)29.6817
2010's19 (46.34)24.3611
2020's13 (31.71)2.80

Authors

AuthorsStudies
Zhang, L1
Zhang, G1
Xu, S1
Song, Y1
Liang, R1
Wong, KH1
Yang, Y1
Duan, Y1
Chen, M1
Wu, JJ1
Zhang, J3
Xia, CY1
Ding, K1
Li, XX1
Pan, XG1
Xu, JK1
He, J1
Zhang, WK1
Buľková, V1
Vargová, J3
Babinčák, M1
Jendželovský, R3
Zdráhal, Z1
Roudnický, P1
Košuth, J1
Fedoročko, P3
de Morais, FAP1
Balbinot, RB1
Bakoshi, ABK1
Lazarin-Bidoia, D1
da Silva Souza Campanholi, K1
da Silva Junior, RC1
Gonçalves, RS1
Ueda-Nakamura, T1
de Oliveira Silva, S1
Caetano, W1
Nakamura, CV1
Pevná, V1
Zauška, Ľ1
Benziane, A1
Vámosi, G1
Girman, V1
Miklóšová, M1
Zeleňák, V1
Huntošová, V2
Almáši, M1
Borghi-Pangoni, FB1
Junqueira, MV1
Bruschi, ML1
Ke, Z1
Xie, A1
Chen, J2
Zou, Z1
Shen, L1
Dai, Y1
Zou, D1
Han, X1
Taratula, O2
Xu, K2
St Lorenz, A1
Moses, A1
Jahangiri, Y1
Yu, G1
Farsad, K1
Teng, X1
Li, F1
Lu, C1
Li, B1
Verebová, V1
Beneš, J1
Staničová, J1
Li, Y2
Wang, S1
Jiang, X1
Wang, X1
Zhou, X1
Wan, L1
Zhao, H1
Zhou, Z1
Gao, L1
Huang, G1
Ni, Y6
He, X1
Dong, X1
Zeng, Y1
Zhang, Z1
Fu, J1
You, L1
He, Y1
Hao, Y1
Gu, Z1
Yu, Z1
Qu, C1
Yin, X1
Ni, J1
Cruz, LJ1
Mikeš, J2
Mikešová, L2
Kuchárová, B2
Čulka, Ľ1
Fedr, R1
Remšík, J1
Souček, K1
Kozubík, A1
Geng, C1
Zhang, Y1
Hidru, TH1
Zhi, L1
Tao, M1
Zou, L1
Chen, C1
Li, H1
Liu, Y2
Garg, AD4
Dudek, AM1
Ferreira, GB1
Verfaillie, T1
Vandenabeele, P3
Krysko, DV3
Mathieu, C1
Agostinis, P7
Cona, MM2
Alpizar, YA1
Li, J1
Bauwens, M2
Feng, Y2
Sun, Z2
Chen, F2
Talavera, K1
de Witte, P5
Verbruggen, A2
Oyen, R2
Barras, A1
Boussekey, L1
Courtade, E1
Boukherroub, R1
Koole, M1
Jendželovská, Z1
Kovaľ, J1
Shao, H1
Dai, X1
Elsen, S1
Saw, CL1
Heng, PW1
Olivo, M5
Karioti, A1
Bilia, AR1
Ni, G1
Chi, M1
Marysael, T2
Lerut, E1
Barliya, T1
Mandel, M1
Livnat, T1
Weinberger, D1
Lavie, G1
Fu, CY1
Raghavan, V1
Lau, WK1
Bormans, G1
Rozenski, J1
Krammer, B2
Verwanger, T1
Buzova, D1
Petrovajova, D1
Kasak, P1
Nadova, Z1
Jancura, D1
Sureau, F1
Miskovsky, P1
Ali, SM1
Piette, J2
Volanti, C1
Vantieghem, A2
Matroule, JY2
Habraken, Y1
Chin, W2
Lau, W1
Lay, SL1
Wei, KK1
Kubin, A1
Wierrani, F1
Burner, U1
Alth, G1
Grünberger, W1
Kiesslich, T1
Plaetzer, K1
Kocanova, S1
Buytaert, E1
Golab, J1
Merlevede, W1
de Witte, PA1

Reviews

15 reviews available for hypericin and Neoplasms

ArticleYear
Recent advances of quinones as a privileged structure in drug discovery.
    European journal of medicinal chemistry, 2021, Nov-05, Volume: 223

    Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Communicable Diseases; Drug

2021
Hypericin: A natural anthraquinone as promising therapeutic agent.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 111

    Topics: Anthracenes; Anthraquinones; Humans; Neoplasms; Photochemotherapy

2023
Biophysical Characterization and Anticancer Activities of Photosensitive Phytoanthraquinones Represented by Hypericin and Its Model Compounds.
    Molecules (Basel, Switzerland), 2020, Dec-01, Volume: 25, Issue:23

    Topics: Animals; Anthracenes; Anthraquinones; Antineoplastic Agents; Humans; Neoplasms; Perylene; Photochemo

2020
Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.
    The Journal of pharmacy and pharmacology, 2021, Mar-08, Volume: 73, Issue:4

    Topics: Anthracenes; Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasms; Perylene; Photoch

2021
Sonodynamic therapy: A potential treatment for atherosclerosis.
    Life sciences, 2018, Aug-15, Volume: 207

    Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Atherosclerosis; Berberine; Cell Death; Chal

2018
ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2014, Volume: 13, Issue:3

    Topics: Animals; Anthracenes; Autophagy; Cell Death; Endoplasmic Reticulum Stress; Humans; Immune System Phe

2014
Potentiation of the photodynamic action of hypericin.
    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2008, Volume: 27, Issue:1

    Topics: Adjuvants, Pharmaceutic; Animals; Anthracenes; Combined Modality Therapy; Humans; Neoplasms; Perylen

2008
Hypericins as potential leads for new therapeutics.
    International journal of molecular sciences, 2010, Feb-04, Volume: 11, Issue:2

    Topics: Anthracenes; Anti-Infective Agents; Antidepressive Agents; Cell Survival; Humans; Hypericum; Neoplas

2010
New frontier in hypericin-mediated diagnosis of cancer with current optical technologies.
    Annals of biomedical engineering, 2012, Volume: 40, Issue:2

    Topics: Anthracenes; Diagnostic Imaging; Fluorescence; Humans; Neoplasms; Perylene; Photochemotherapy; Photo

2012
Molecular response to hypericin-induced photodamage.
    Current medicinal chemistry, 2012, Volume: 19, Issue:6

    Topics: Animals; Anthracenes; Antineoplastic Agents; Humans; Neoplasms; Perylene; Photochemotherapy; Photose

2012
Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers.
    Biochemical pharmacology, 2003, Oct-15, Volume: 66, Issue:8

    Topics: Animals; Anthracenes; Apoptosis; Cell Division; Humans; Mitochondria; Neoplasms; Perylene; Photochem

2003
Hypericin--the facts about a controversial agent.
    Current pharmaceutical design, 2005, Volume: 11, Issue:2

    Topics: Animals; Anthracenes; Austria; Cell Death; Humans; Molecular Structure; Neoplasms; Perylene; Photoch

2005
Perylenequinones in photodynamic therapy: cellular versus vascular response.
    Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2006, Volume: 25, Issue:1-2

    Topics: Animals; Anthracenes; Apoptosis; Blood Vessels; Humans; Neoplasms; Perylene; Phenol; Photochemothera

2006
Cellular mechanisms and prospective applications of hypericin in photodynamic therapy.
    Current medicinal chemistry, 2006, Volume: 13, Issue:18

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Humans; Hydrogen-Io

2006
Hypericin in cancer treatment: more light on the way.
    The international journal of biochemistry & cell biology, 2002, Volume: 34, Issue:3

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cytochrome c Group; HeLa Cells; Humans; Hypericum; Mi

2002

Other Studies

26 other studies available for hypericin and Neoplasms

ArticleYear
ROS-responsive dexamethasone micelles normalize the tumor microenvironment enhancing hypericin in cancer photodynamic therapy.
    Biomaterials science, 2022, Feb-15, Volume: 10, Issue:4

    Topics: Anthracenes; Cell Line, Tumor; Dexamethasone; Endothelial Cells; Micelles; Neoplasms; Perylene; Phot

2022
New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 163

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Basic Helix-Loop-Helix Transcription Factor

2023
Advanced theranostic nanoplatforms for hypericin delivery in the cancer treatment.
    Journal of photochemistry and photobiology. B, Biology, 2023, Volume: 247

    Topics: Anthracenes; Caco-2 Cells; Humans; Lipids; Neoplasms; Perylene; Photochemotherapy; Polymers; Precisi

2023
Effective transport of aggregated hypericin encapsulated in SBA-15 nanoporous silica particles for photodynamic therapy of cancer cells.
    Journal of photochemistry and photobiology. B, Biology, 2023, Volume: 247

    Topics: Anthracenes; Nanopores; Neoplasms; Perylene; Photochemotherapy; Photosensitizing Agents; Silicon Dio

2023
Physicochemical stability of bioadhesive thermoresponsive platforms for methylene blue and hypericin delivery in photodynamic therapy.
    Pharmaceutical development and technology, 2020, Volume: 25, Issue:4

    Topics: Acrylates; Adhesives; Anthracenes; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberati

2020
Naturally available hypericin undergoes electron transfer for type I photodynamic and photothermal synergistic therapy.
    Biomaterials science, 2020, May-06, Volume: 8, Issue:9

    Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Electrons; Female; HeLa Cells; Humans

2020
Biodegradable Hypericin-Containing Nanoparticles for Necrosis Targeting and Fluorescence Imaging.
    Molecular pharmaceutics, 2020, 05-04, Volume: 17, Issue:5

    Topics: Animals; Anthracenes; Cell Line, Tumor; Female; Humans; Mice; Nanoparticles; Necrosis; Neoplasms; Op

2020
Carbon dot-assisted luminescence of singlet oxygen: the generation dynamics but not the cumulative amount of singlet oxygen is responsible for the photodynamic therapy efficacy.
    Nanoscale horizons, 2020, 06-01, Volume: 5, Issue:6

    Topics: Animals; Anthracenes; Antineoplastic Agents; Carbon; Female; HeLa Cells; Humans; Imidazoles; Lumines

2020
Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy.
    International journal of pharmaceutics, 2021, Apr-15, Volume: 599

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Anthracenes; Cyclodextrins; Excipients; Humans; Neoplasms; Peryle

2021
Hypericin affects cancer side populations via competitive inhibition of BCRP.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 99

    Topics: Aldehyde Dehydrogenase; Animals; Anthracenes; ATP Binding Cassette Transporter, Subfamily B, Member

2018
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death.
    Autophagy, 2013, Volume: 9, Issue:9

    Topics: Adenosine Triphosphate; Anthracenes; Autophagy; Autophagy-Related Protein 5; Calreticulin; CD4-Posit

2013
Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.
    Pharmaceutical research, 2014, Volume: 31, Issue:2

    Topics: Animals; Anthracenes; Antineoplastic Agents; Chemistry, Pharmaceutical; Dimethyl Sulfoxide; Iodine R

2014
Hypericin-loaded lipid nanocapsules for photodynamic cancer therapy in vitro.
    Nanoscale, 2013, Nov-07, Volume: 5, Issue:21

    Topics: Anthracenes; Cell Line; Cell Survival; Drug Carriers; HeLa Cells; Humans; Hypericum; Light; Lipids;

2013
Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic.
    International journal of oncology, 2014, Volume: 44, Issue:3

    Topics: Animals; Anthracenes; Female; Humans; Iodine Radioisotopes; Male; Neoplasms; Perylene; Radiation Dos

2014
Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status.
    Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:3

    Topics: Anthracenes; ATP-Binding Cassette Transporters; Caspase 3; Cell Death; Cell Line, Tumor; Drug Synerg

2015
Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.
    Oncotarget, 2015, Jun-10, Volume: 6, Issue:16

    Topics: Animals; Anthracenes; Autoradiography; Disease Models, Animal; Iodine Radioisotopes; Necrosis; Neopl

2015
Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
    Oncotarget, 2015, Sep-29, Volume: 6, Issue:29

    Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Calreticulin; Cancer Vacc

2015
The possible use of hypericin to overcome drug resistance in cancer treatment.
    Chemico-biological interactions, 2011, Apr-25, Volume: 190, Issue:2-3

    Topics: Anthracenes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochr

2011
Influence of the vascular damaging agents DMXAA and ZD6126 on hypericin distribution and accumulation in RIF-1 tumors.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:11

    Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred C3H; Necrosis; Neo

2011
Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Anthracenes; Antineoplastic Agents; Blotting, Western; Cathepsin B; Cell Hypoxia; Cell Line; Cell Li

2011
Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Animals; Anthracenes; Antineoplastic Agents; Avidin; Biotin; Biotinylation; Cell Line, Tumor; Contra

2012
Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin.
    Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:2

    Topics: Animals; Anthracenes; Anthracyclines; Apoptosis; Cell Line; Dendritic Cells; Hematoporphyrin Photora

2012
Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells.
    International journal of pharmaceutics, 2012, Oct-15, Volume: 436, Issue:1-2

    Topics: Anthracenes; Cell Line, Tumor; Dextrans; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interact

2012
Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells.
    International journal of oncology, 2002, Volume: 21, Issue:3

    Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Colonic Neoplasms; Cytochrome c Group; Humans; Intrac

2002
Photodynamic-induced vascular damage of the chick chorioallantoic membrane model using perylenequinones.
    International journal of oncology, 2004, Volume: 25, Issue:4

    Topics: Animals; Anthracenes; Blood Vessels; Chickens; Chorioallantoic Membrane; Neoplasms; Perylene; Photoc

2004
Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy.
    Apoptosis : an international journal on programmed cell death, 2007, Volume: 12, Issue:4

    Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Enzyme Induction; Enzyme Inhibitors; Heme Oxygenase-1; Hum

2007